grant

HEXAGEN Harnessing haematopoietic stem cell EX vivo Adaptation for GENe therapy

Organization UKRILocation United Kingdom
UKRIUK ResearchGrantActive
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Description preview

Haematopoietic Stem Cell (HSC) Gene Therapy (GT) is no longer an experimental treatment, but a medicinal product and the only curative option for many monogenic inherited disorders. It relies on genetic correction of HSCs, the only cells driving lifelong blood production when grafted back into the patient. Owing to decades of optimization, current…

🔒

Full details available on the Agency plan

Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.

Start 7-day free trial — $29.99/mo →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →
HEXAGEN Harnessing haematopoietic stem cell EX vivo Adaptation for GENe therapy — UKRI | United Kingdom | Dev Procure